Drug Profile
Furaprevir - Dongguan HEC TaiGen Biopharmaceuticals
Alternative Names: TG-2349Latest Information Update: 22 Mar 2022
Price :
$50
*
At a glance
- Originator TaiGen Biotechnology
- Developer Dongguan HEC TaiGen Biopharmaceuticals; TaiGen Biotechnology
- Class Antivirals; Benzofurans; Carbamates; Cyclopentanes; Cyclopropanes; Pyrimidines; Pyrroles
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hepatitis C
Most Recent Events
- 22 Mar 2022 Furaprevir is still in phase II trials for Hepatitis C in Taiwan and USA (TaiGen Biotechnology pipeline, March 2022)
- 22 Mar 2022 Furaprevir is still in phase III trials for Hepatitis C in China (TaiGen Biotechnology pipeline, March 2022)
- 09 Feb 2021 Dongguan HEC TaiGen Biopharmaceuticals completes a phase III trial in Hepatitis C in China (NCT04155515)